An audit conducted by a federal watchdog uncovered that Medicare disbursed an estimated $380 million to $400 million over six years for organs not used in Medicare-covered transplants. This has led to scrutiny over how transplant centers are reimbursed and whether federal guidance conflicts with current laws. The Department of Health and Human Services Office of Inspector General (OIG) identified a gap between federal law and guidance from the Centers for Medicare & Medicaid Services (CMS).
Conflicting Guidance
The audit revealed that Medicare paid transplant centers for organs that were either used in non-Medicare patients or went unused. “Medicare was compensating acquisition costs under guidance that assumed each organ would ultimately serve a Medicare patient,” Michael Ryan, a finance expert, explained. “This misalignment between CMS guidance and federal law resulted in unintentional taxpayer expenses.”
Why It Matters
These findings surface at a time when lawmakers are scrutinizing federal healthcare spending, especially with Medicare’s ongoing financial constraints. Organ transplantation ranks among the costliest services funded by Medicare, with over $3 billion spent on organ acquisition in 2023, covering roughly 39,000 organs.
The report suggests these reimbursement practices may not comply with federal law, potentially costing taxpayers hundreds of millions. Auditors discovered a conflict between CMS guidance and statutory requirements, impacting how funds are allocated.
What To Know
Federal law restricts Medicare to reimburse only for organs used in Medicare procedures. Still, CMS’s guidance suggests many transferred organs be treated as “Medicare usable.” In practice, some organs benefit non-Medicare patients, while others remain unused. This discrepancy between guidance and law leads to unwarranted reimbursements.
Audit Findings
Auditors reviewed a sample of 180 organs from 12 centers, associated with $12.3 million in Medicare reimbursements. Key findings include:
- Medicare wrongly paid around $2.8 million for 55 organs that were not eligible under federal rules.
- 43 organs went to non-Medicare patients and 12 remained unused.
The broader estimate indicated Medicare inadvertently paid $380 million for similar cases over six years.
Some argue that this waste, when spread over six years, amounts to a minor 2% of total spending. Financial expert Drew Powers noted that, given the total $18 billion spent, $17.62 billion was used correctly, reflecting reasonable efficiency.
Causes and Recommendations
The OIG explained that federal law restricts reimbursement to organs used in Medicare transplants. However, CMS guidance presumes transplanted organs will eventually serve Medicare enrollees—a presumption sometimes proven false, leading to shared acquisition costs without corresponding benefits.
The OIG advised CMS to direct contractors to recover $154,210 from two centers lacking sufficient documentation. They also urged revising Medicare guidance to ensure only organs transplanted into Medicare enrollees are reported as Medicare-usable.